Category: Biotech
Accelerating Approval Pathway For Phase III Ovarian Cancer Trial A late-stage biotech was developing a combination therapy for a rare form of ovarian cancer. It is challenging to diagnose, difficult to treat due to its chemo-resistance, and at the time, there were no approved treatments specifically for this indication. Read Now
Artificial Intelligence in Oncology Clinical Trials Transforming drug development Artificial intelligence (AI) is revolutionizing nearly every aspect of our work and Read Now
Focused Monitoring Support for Rare Disease Study A small biotech needed functional support for a Phase III rare disease study. Although a contract
existed between the biotech and a clinical research organization (CRO), the study timelines and budget
had slipped. The biotech hired Catalyst Flex to reverse that trend and ultimately saved ~$1 million. Read Now
Impacts of Project Optimus on Oncology Trial Costs Exploring creative financial solutions for biotechs Navigating the evolving landscape of early-phase drug development has Read Now
Navigating the Changing Landscape of Clinical Trials Takeaways from the Clinical Trials in Oncology East Coast I was thrilled to recently chair Read Now
Policy Changes from Patient Support to Location BIO International 2024 Highlights Biotech companies from all over the globe, including those researching novel, Read Now
Benefits of Working with Catalyst Oncology versus a Large Generalist CRO Oncology drug development continues to increase in its complexity. Large contract research organizations (CROs) are Read Now
Providing Support to Succeed Catalyst Flex delivers clinical monitoring oversight experts on Phase III global study Situation A small Read Now
Webinar: Clinical Trial Flexibility and Customization Needs that Are Required by Biotechs and Next-generation Therapies COVID-19 has ushered in new challenges when conducting clinical trials, but mid-tier biotech companies have Read Now